Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 149 clinical trials
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the

  • 164 views
  • 29 Apr, 2021
  • 225 locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts

  • 32 views
  • 29 Apr, 2021
  • 149 locations
featured
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

navitoclax alone or when added to ruxolitinib in participants with myelofibrosis.

  • 251 views
  • 29 Apr, 2021
  • 135 locations
featured
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of INCB057643 as monotherapy for participants with relapsed or refractory myelofibrosis.

  • 0 views
  • 29 Sep, 2020
  • 2 locations
featured
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

The purpose of this study is to see if the study drugs, ABBV-105, upadacitinib (ABT-494), or both ABBV-105 and upadacitinib (ABT-494) in combination (ABBV-599) are safe, tolerable, and effective in treating your moderately to severely active systemic lupus erythematosus (SLE).  

cyclosporine
prednisone
  • 61 views
  • 23 Nov, 2020
  • 1 location
featured
An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis

The purpose of this study is to evaluate the efficacy and safety of itacitinib combined with low-dose ruxolitinib or itacitinib alone in subjects with myelofibrosis.  

myelofibrosis
myeloproliferative disorders
leukemia
  • 141 views
  • 14 Dec, 2020
  • 11 locations
featured
Myelofibrosis

Myelofibrosis

  • 532 views
  • 08 Nov, 2020
  • 1 location
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

myeloproliferative/myelodysplastic disorders
myelofibrosis
myeloproliferative syndromes
myeloproliferative disorder
myeloproliferative disorders
  • 0 views
  • 22 Jan, 2021
  • 1 location
featured
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

This is an open-label, nonrandomized, Phase 1/2 study to evaluate the safety and tolerability, the PK, the PD, and the efficacy (antianemic activity) of INCB000928 administered alone or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. INCB000928 tablets will be administered orally …

anemia
  • 67 views
  • 05 Oct, 2020
  • 1 location
featured
IBS...Irritable Bowel Syndrome

IBS...Irritable Bowel Syndrome

  • 1014 views
  • 08 Nov, 2020
  • 2 locations